TY - JOUR AU - Krányák, Dóra AU - Novák, Adél AU - Pataky, Noémi AU - Sághy, László AU - Vámos, Máté AU - Szili-Török, Tamás AU - Pap, Róbert ED - Krányák, Dóra / Collaborator ED - Novák, Adél / Collaborator ED - Pataky, Noémi / Collaborator ED - Benák, Attila / Collaborator ED - Bencsik, Gábor / Collaborator ED - Makai, Attila / Collaborator ED - Miklós, Márton / Collaborator ED - Sághy, László / Collaborator ED - Vámos, Máté / Collaborator ED - Szili-Török, Tamás / Collaborator ED - Pap, Róbert / Collaborator TI - Utility of Pharmacologic Conversion of Persistent Atrial Fibrillation by Amiodarone as a Predictor of Outcome After Pulmonary Vein Isolation JF - JOURNAL OF CARDIOVASCULAR ELECTROPHYSIOLOGY J2 - J CARDIOVASC ELECTR VL - 37 PY - 2026 IS - 1 SP - 90 EP - 95 PG - 6 SN - 1045-3873 DO - 10.1111/jce.70155 UR - https://m2.mtmt.hu/api/publication/36442661 ID - 36442661 LA - English DB - MTMT ER - TY - JOUR AU - Vámos, Máté AU - Benák, Attila AU - Sághy, László AU - Szili-Török, Tamás TI - Accidental extraction of a lead remnant with a leadless pacemaker delivery system. [case report] TS - [case report] JF - HEARTRHYTHM CASE REPORTS J2 - HEARTRHYTHM CASE REP VL - 11 PY - 2025 IS - 2 SP - 129 EP - 132 PG - 4 SN - 2214-0271 DO - 10.1016/j.hrcr.2024.10.023 UR - https://m2.mtmt.hu/api/publication/35526355 ID - 35526355 N1 - Szövegében 3 oldalnál rövidebb esetismertetés, ezért besorolása rövid közlemény az MTA V. Osztályának ajánlása alapján. (PL, SZTE admin5, 2025.03.11.) Case reports rovat LA - English DB - MTMT ER - TY - JOUR AU - Pólos-Merkel, Eperke Dóra AU - Hatala, Robert AU - Szigeti, Mátyás AU - Schwertner, Walter Richard AU - Lakatos, Bálint AU - Behon, Anett AU - Goscinska-Bis, Kinga AU - Milasinovic, Goran AU - Papp, Roland AU - Ruppert, Mihály AU - Sághy, László AU - Clemens, Marcell AU - Solomon, Scott D AU - Kutyifa, Valentina AU - Kovács, Attila AU - Kosztin, Annamária AU - Merkely, Béla Péter TI - Upgrading Right Ventricular Pacing to Cardiac Resynchronization in HFrEF Patients Improves Symptoms and Functional Outcomes JF - JACC-HEART FAILURE J2 - JACC HEART FAILURE VL - 13 PY - 2025 IS - 2 SP - 265 EP - 273 PG - 9 SN - 2213-1779 DO - 10.1016/j.jchf.2024.09.011 UR - https://m2.mtmt.hu/api/publication/35618315 ID - 35618315 N1 - Funding Agency and Grant Number: National Research Development and Innovation Fund of Hungary [NVKP_16-1-2016-0017]; European Union [NVKP_16, RRF-2.3.1-21-2 022-00003]; Abbott; Biotronik; Slovak Research and Development Agency; European Society of Cardiology; Pfizer; Alnylam; MyoKardia; NovoNordisk; Theracos; Arena; Boston Scientific, ZOLL; NIH; Bolyai Research Scholarship; FK 'OTKA' Research Grant from NKFIH; Argus Cognitive, Inc; Medtronic; Boston Scientific; (Hungarian Society of Cardiology); Boehringer Ingelheim [TKP2021-NVA-12]; Daiichi Sankyo; DUKE Clinical Institut; Heart and Vascular Center of Semmelweis University; National Heart Program; Ministry of Innovation and Technology of Hungary from the Na-tional Research, Development and Innovation Fund; [TKP2021-NVA] Funding text: The BUDAPEST CRT Upgrade study was an investigator-initiated research trial, sponsored by Semmelweis University, receiving an unrestricted grant from Boston Scientific to conduct the study. The trial was supported by the National Heart Program (Project number NVKP_16-1-2016-0017) with support provided by the National Research Development and Innovation Fund of Hungary, financed under the NVKP_16 funding scheme. Additionally, Project number RRF-2.3.1-21-2 022-00003 has been implemented with the support provided by the European Union. Dr Hatala has received institutional grants from Abbott, Biotronik, and Slovak Research and Development Agency; honoraria from Abbott and Medtronic; travel grants from the European Society of Cardiology and Pfizer; and he is also the president of the Slovak Heart Rhythm Association. Dr Papp has received payment or honoraria from Medtronic and Biotronik for lectures and presentations. Dr Solomon has received grants to his institution from Acte lion, Alnylam, Amgen, AstraZeneca, Bellerophon, Bayer, BMS, Celladon, Cytokinetics, Eidos, Gilead, GSK, Ionis, Lilly, Mesob last, MyoKardia, NIH/NHLBI, Neurotronik, Novartis, NovoNordisk, Respicardia, Sanofi Pasteur, Theracos, and US2.AI; and consulting fees outside of the scope of the current work from Abbott, Action, Akros, Alnylam, Amgen, Arena, AstraZeneca, Bayer, Boehringer Ingelheim, BMS, Cardior, Cardurion, Corvia, Cytokinetics, Daiichi-Sankyo, GSK, Lilly, Merck, Myokardia, Novartis, Roche, Theracos, Quantum Genomics, Cardurion, Janssen, Cardiac Dimensions, Tenaya, Sanofi-Pasteur, Dinaqor, Tremeau, CellProTh era, Moderna, American Regent, Sarepta, Lexicon, Anacardio, Akros, and Valo. Dr Kutyifa has received grants from Boston Scientific, ZOLL, Biotronik, Spire Inc, and NIH; consulting fees from Biotronik and Zoll; and payment or honoraria for lectures from Abbott Medical and Medtronic. Dr Kovacs has received grants from Bolyai Research Scholarship and FK 'OTKA' Research Grant from NKFIH outside of the submitted work; stock from CardioSight Inc, and stock option from Argus Cognitive Inc outside of the submitted work; and personal fees from Argus Cognitive, Inc, and CardioSight Hungary LLC outside of the submitted work. Dr Kosz tin has received grants from Bolyai Research Scholarship outside of the submitted work; consulting fees from Medtronic; honoraria from AstraZeneca, Bayer, Boehringer Ingelheim, Biotronik, and Novartis; payment for expert testimony from Boehringer Ingelheim and Boston Scientific; travel grants from AstraZeneca and Novartis; participation on a data safety monitoring board or advisory board for Boehringer Ingelheim and Boston Scientific; and role in other board and committee (committee member of Hungarian Society of Cardiology and secretary of the Working Group on Cardiac Arrhythmias and Pacing, Hungarian Society of Cardiology) . Dr Merkely has received speaker fees from Boehringer Ingelheim, Daiichi Sankyo, DUKE Clinical Institut, and Novartis; and has received institutional grants for the Heart and Vascular Center of Semmelweis University from Boston Scientific, Biotronik, Boehringer Ingelheim, DUKE Clinical Institut, Eli Lilly, and Novartis; grants from Boston Scientific, NRDIF Hungary, and National Heart Program during the conduct of the study; personal fees from Biotronik, Abbott, AstraZeneca, Novartis, and Boehringer Ingelheim; and grants from Medtronic outside of the submitted work. TKP2021-NVA-12 has been implemented with the support provided by the Ministry of Innovation and Technology of Hungary from the National Research, Development and Innovation Fund, financed under the TKP2021-NVA funding scheme. All other authors have reported that they have no relationships relevant to the contents of this paper to disclose.r NVKP_16-1-2016-0017) with support provided by the National Research Development and Innovation Fund of Hungary, financed under the NVKP_16 funding scheme. Additionally, Project number RRF-2.3.1-21-2 022-00003 has been implemented with the support provided by the European Union. Dr Hatala has received institutional grants from Abbott, Biotronik, and Slovak Research and Development Agency; honoraria from Abbott and Medtronic; travel grants from the European Society of Cardiology and Pfizer; and he is also the presi-dent of the Slovak Heart Rhythm Association. Dr Papp has received payment or honoraria from Medtronic and Biotronik for lectures and presentations. Dr Solomon has received grants to his institution from Acte lion, Alnylam, Amgen, AstraZeneca, Bellerophon, Bayer, BMS, Celladon, Cytokinetics, Eidos, Gilead, GSK, Ionis, Lilly, Mesob last, MyoKardia, NIH/NHLBI, Neurotronik, Novartis, NovoNordisk, Respi-cardia, Sanofi Pasteur, Theracos, and US2.AI; and consulting fees outside of the scope of the current work from Abbott, Action, Akros, Alnylam, Amgen, Arena, AstraZeneca, Bayer, Boehringer Ingelheim, BMS, Cardior, Cardurion, Corvia, Cytokinetics, Daiichi-Sankyo, GSK, Lilly, Merck, Myokardia, Novartis, Roche, Theracos, Quantum Geno-mics, Cardurion, Janssen, Cardiac Dimensions, Tenaya, Sanofi-Pas-teur, Dinaqor, Tremeau, CellProTh era, Moderna, American Regent, Sarepta, Lexicon, Anacardio, Akros, and Valo. Dr Kutyifa has received grants from Boston Scientific, ZOLL, Biotronik, Spire Inc, and NIH; consulting fees from Biotronik and Zoll; and payment or honoraria for lectures from Abbott Medical and Medtronic. Dr Kovacs has received grants from Bolyai Research Scholarship and FK 'OTKA' Research Grant from NKFIH outside of the submitted work; stock from Car-dioSight Inc, and stock option from Argus Cognitive Inc outside of the submitted work; and personal fees from Argus Cognitive, Inc, and CardioSight Hungary LLC outside of the submitted work. Dr Kosz tin has received grants from Bolyai Research Scholarship outside of the submitted work; consulting fees from Medtronic; honoraria from AstraZeneca, Bayer, Boehringer Ingelheim, Biotronik, and Novartis; payment for expert testimony from Boehringer Ingelheim and Boston Scientific; travel grants from AstraZeneca and Novartis; participation on a data safety monitoring board or advisory board for Boehringer Ingelheim and Boston Scientific; and role in other board and com-mittee (committee member of Hungarian Society of Cardiology and secretary of the Working Group on Cardiac Arrhythmias and Pacing, Hungarian Society of Cardiology) . Dr Merkely has received speaker fees from Boehringer Ingelheim, Daiichi Sankyo, DUKE Clinical Institut, and Novartis; and has received institutional grants for the Heart and Vascular Center of Semmelweis University from Boston Scientific, Biotronik, Boehringer Ingelheim, DUKE Clinical Institut, Eli Lilly, and Novartis; grants from Boston Scientific, NRDIF Hungary, and National Heart Program during the conduct of the study; personal fees from Biotronik, Abbott, AstraZeneca, Novartis, and Boehringer Ingelheim; and grants from Medtronic outside of the submitted work. TKP2021-NVA-12 has been implemented with the support provided by the Ministry of Innovation and Technology of Hungary from the Na-tional Research, Development and Innovation Fund, financed under the TKP2021-NVA funding scheme. All other authors have reported that they have no relationships relevant to the contents of this paper to disclose. AB - In the BUDAPEST (Biventricular Upgrade on left ventricular reverse remodeling and clinical outcomes in patients with left ventricular Dysfunction and intermittent or permanent APical/SepTal right ventricular pacing)-CRT Upgrade randomized trial, the authors have demonstrated improved mortality and morbidity after cardiac resynchronization therapy (CRT) upgrade in patients with heart failure with reduced ejection fraction (HFrEF) with high right ventricular (RV) pacing burden.This substudy sought to examine the impact of CRT upgrade on symptoms, functional outcome, and exercise capacity.In the BUDAPEST-CRT Upgrade trial, 360 HFrEF patients with pacemaker or implantable cardioverter-defibrillator (ICD) and ≥20% RV pacing burden were randomly assigned (3:2) to cardiac resynchronization therapy with defibrillator (CRT-D) upgrade (n = 215) or ICD (n = 145). The prespecified tertiary endpoints were changes in quality of life (QoL) (EQ-5D-3L), NYHA functional class, 6-minute walk test, and N-terminal pro-B-type natriuretic peptide (NT-proBNP) levels.Up to 12 months, NYHA functional class improved in the CRT-D upgrade arm compared with ICD only (adjusted OR: 0.50 [95% CI: 0.32-0.80]; P = 0.003). A remarkable decrease was observed in NT-proBNP levels in the CRT-D arm (adjusted difference -1,257 pg/mL [95% CI: -2,287 to -228]; P = 0.017). The progression of age-related worsening of QoL was moderated by CRT-D upgrade (EQ-5D-3L difference by each year: 0.015 [95% CI: 0.005-0.025]; P interaction = 0.003). However, exercise tolerance (6-minute walk test) remained unchanged in both groups.HFrEF patients with pacemaker/ICD and ≥20% RV pacing burden receiving CRT upgrade showed a substantial improvement in NYHA functional class and decrease in natriuretic peptide levels, as compared with ICD alone. Moreover, CRT-D upgrade could moderate the progression of worsening of QoL attributed to ageing in this vulnerable, elderly patient population. (Biventricular Upgrade on left ventricular reverse remodeling and clinical outcomes in patients with left ventricular Dysfunction and intermittent or permanent APical/SepTal right ventricular pacing [BUDAPEST]-CRT Upgrade trial). LA - English DB - MTMT ER - TY - JOUR AU - Krányák, Dóra AU - Sághy, László AU - Pap, Róbert TI - A bal kamrai Purkinje-hálózat distalis arborizációjának katéteres ablatiója a visszatérő kamrafibrilláció terápiájában [Catheter ablation of the distal arborization of the left ventricular Purkinje network in the therapy of recurrent ventricular fibrillation]. [esetismertetés] TS - [esetismertetés] JF - ORVOSI HETILAP J2 - ORV HETIL VL - 166 PY - 2025 IS - 8 SP - 307 EP - 312 PG - 6 SN - 0030-6002 DO - 10.1556/650.2025.33209 UR - https://m2.mtmt.hu/api/publication/35784598 ID - 35784598 N1 - Szövegében 3 oldalas esetismertetés, ezért besorolása rövid közlemény az MTA V. Osztályának ajánlása alapján. (nte, SZTE admin5, 2025-02-25) AB - Egyre több vizsgálat eredménye utal a Purkinje-hálózat és a Purkinje-myocardium-junctio szerepére malignus kamrai arrhythmiák kiváltásában. A bal kamrai Purkinje-hálózat distalis arborizációjának rádiófrekvenciás katéterablatiója befolyásolhatja a kamrafibrilláció ismétlődését. Három beteg (mind férfi, életkor: 52 ± 6,6 év) esetében került sor amiodaron ellenére gyakran visszatérő kamrafibrilláció miatt a distalis bal kamrai Purkinje-hálózat ablatiójára. Egyikük hypertrophiás, egy másik ischaemiás cardiomyopathiában szenvedett, a harmadik esetében idiopathiás kamrafibrilláció volt a diagnózis. A célpont azonosítása izoproterenolinfúzióval indukálható, Purkinje-eredetű kamrai extrasystole térképezése (2 beteg esetében) és a klinikai EKG-dokumentáció, illetve a beültethető kardioverter-defibrillátor által rögzített regisztrátumok alapján végzett ’pace-map’ révén (2 beteg) történt. A rádiófrekvenciás ablatio célpontja a Purkinje-potenciálok által azonosított, bal kamrai posterior fasciculus mellett egy esetben magában foglalta az anterior fasciculus distalis arborizációjának területét is. A beavatkozást követő 17 ± 11 hónapos utánkövetés során egy beteg esetében jelentkezett – a korábbiaknál ritkábban – malignus kamrai arrhythmia. Különböző eredetű, visszatérő kamrafibrilláció esetén a bal kamrai Purkinje-hálózat distalis arborizációjának katéteres ablatiója csökkentheti a malignus kamrai arrhythmiák ismétlődését. Orv Hetil. 2025; 166(8): 307–312. LA - Hungarian DB - MTMT ER - TY - JOUR AU - Riesz, Tamás János AU - Bencsik, Gábor AU - Sághy, László AU - Pap, Róbert TI - Does organized atrial tachycardia after a pulmonary vein isolation-only procedure portend better outcome of repeat ablation compared to recurrent atrial fibrillation? JF - JOURNAL OF ARRHYTHMIA J2 - J ARRHYTHMIA VL - 41 PY - 2025 IS - 2 PG - 8 SN - 1880-4276 DO - 10.1002/joa3.70049 UR - https://m2.mtmt.hu/api/publication/36067221 ID - 36067221 AB - Better outcome has been suggested for repeat procedures after atrial fibrillation (AF) ablation, when recurrence presented as organized atrial tachycardia (OAT) compared to recurrent AF. However, this contradicts the finding of more advanced atrial remodeling in patients with OAT recurrence and may be related to iatrogenesis by substrate modification during the index procedure. Therefore, we examined the prognostic significance of the type of recurrent arrhythmia after pulmonary vein isolation (PVI) without additional substrate modification.We included 185 patients (88 female, 64 ± 9 years) undergoing repeat ablation after index PVI for recurrent OAT (24%) or AF (76%). The recurrence rate, arrhythmia-free survival time, and the type of further recurrences were recorded.There was no difference in the rate and mean time of arrhythmia-free survival between patients with OAT versus AF recurrence after the first (49% vs. 52%, p = .72 and 51.08 ± 6.66 vs. 53.37 ± 4.75 months, p = .54, respectively) and last (60% vs. 58%, p = .80 and 63.2 ± 7.04 vs. 61.2 ± 5.32 months, p = .23, respectively) redo procedure. AF occurred in the majority of subsequently recurring patients in both groups. No significant difference was found in the outcome of redo procedures between patients with typical flutter and atypical OAT, but a higher rate of successful rhythm control was observed in those with paroxysmal, as compared to persistent AF recurrence.After a PVI-only index procedure, recurrent OAT is not associated with a better outcome of redo procedures compared to recurrent AF. After repeat ablations, both groups experience AF as the dominant further recurrence. LA - English DB - MTMT ER - TY - JOUR AU - Benák, Attila AU - Ruzsa, Zoltán AU - Vámos, Máté AU - Makai, Attila AU - Szili-Török, Tamás AU - Sághy, László TI - Pacemaker és ICD elektróda endocarditis asszociált vegetációk perkután mechanikus aspirációja fix görbületű hüvely segítségével = Percutaneous mechanical aspiration of lead endocarditis-associated vegetations with fixed curvature sheath JF - CARDIOLOGIA HUNGARICA J2 - CARDIOL HUNG VL - 55 PY - 2025 IS - Suppl A SP - A200 EP - A200 PG - 1 SN - 0133-5596 UR - https://m2.mtmt.hu/api/publication/36149331 ID - 36149331 LA - Hungarian DB - MTMT ER - TY - JOUR AU - Gausz, Flóra Diána AU - Fodor, Dániel AU - Miklós, Márton AU - Benák, Attila AU - Krányák, Dóra AU - Makai, Attila AU - Bencsik, Gábor AU - Pap, Róbert AU - Sághy, László AU - Nemes, Attila AU - Szili-Török, Tamás AU - Vámos, Máté TI - Egy- és kétüregi ICD diszkriminátorok hatékonyságának vizsgálata távellátásba bevont betegeken = Single- versus dual-chamber ICD discriminators for tachyarrhythmia detection: A remote monitoring based, single-center study JF - CARDIOLOGIA HUNGARICA J2 - CARDIOL HUNG VL - 55 PY - 2025 IS - Suppl A SP - A202 EP - A202 PG - 1 SN - 0133-5596 UR - https://m2.mtmt.hu/api/publication/36149358 ID - 36149358 LA - Hungarian DB - MTMT ER - TY - JOUR AU - Morvai-Illés, Blanka AU - Sághy, László AU - Jdid Mahmoud, Saddik AU - Ladóczky-Hulló, Daniella AU - Szabados, Tamara AU - Szili-Török, Tamás AU - Varga, Albert AU - Kovács, László AU - Bencsik, Péter AU - Ágoston, Gergely TI - A fekvőkerékpár-terheléses vizsgálat és a biomarkerek jelentősége szisztémás szklerózisban = The significance of semi-recumbent bicycle stress echocardiography and biomarkers in systemic sclerosis JF - CARDIOLOGIA HUNGARICA J2 - CARDIOL HUNG VL - 55 PY - 2025 IS - Suppl A SP - A230 EP - A230 PG - 1 SN - 0133-5596 UR - https://m2.mtmt.hu/api/publication/36159495 ID - 36159495 LA - Hungarian DB - MTMT ER - TY - JOUR AU - Sághy, László AU - Morvai-Illés, Blanka AU - Jdid Mahmoud, Saddik AU - Kiss-Kovács, Róbert AU - Varga, Albert AU - Ágoston, Gergely TI - Az effort dyspnae pathomechanizmusának modellezése HFpEF-ben = Modeling the pathomechanism of effort dyspnea in HFpEF JF - CARDIOLOGIA HUNGARICA J2 - CARDIOL HUNG VL - 55 PY - 2025 IS - Suppl A SP - A231 EP - A231 PG - 1 SN - 0133-5596 UR - https://m2.mtmt.hu/api/publication/36159500 ID - 36159500 LA - Hungarian DB - MTMT ER - TY - JOUR AU - Pap, Róbert AU - Krányák, Dóra AU - Bencsik, Gábor AU - Vámos, Máté AU - Pataky, Noémi AU - Sághy, László TI - Izolált pulmonális vénában folytatódó lokális fibrilláció: a pitvarfibrilláció sikeres ablációjának jele? = Confi ned fi brillation within isolated pulmonary veins: Fortuitous finding or indicator of successful ablation of atrial fibrillation? JF - CARDIOLOGIA HUNGARICA J2 - CARDIOL HUNG VL - 55 PY - 2025 IS - Suppl A SP - A253 EP - A253 PG - 1 SN - 0133-5596 UR - https://m2.mtmt.hu/api/publication/36159512 ID - 36159512 LA - English DB - MTMT ER -